Trial reportBMC anesthesiology2025
Effect of sugammadex titration versus manufacturer's recommendation for reversal of rocuronium-induced neuromuscular block: a prospective, randomized, controlled trial.
Trial report in BMC anesthesiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
Abstract
backgroundBoth under-dosing and over-dosing of sugammadex for reversing neuromuscular block pose risks to patients, yet the optimal dosage for different degrees of neuromuscular block remains undefined. This study compared titration with single bolus of sugammadex recommended by manufacturer to determine the optimal dose for achieving a train-of-four ratio (TOFR) of 0.9 or greater while minimizing residual paralysis.
methodsPatients were randomly assigned to titrated group or manufacturer-recommended group. In titrated group, sugammadex was given in 50-mg increments every 5 min until a TOFR of 0.9 or greater was reached. In recommended group, a single dose (2 mg/kg or 4 mg/kg) was given based on train-of-four count (TOFC). Neuromuscular block was monitored continuously, and residual paralysis was assessed in the post-anesthesia care unit (PACU).
resultsOf 210 enrolled patients, 205 were evaluated. The median dose of sugammadex for reversing different depths of neuromuscular block induced by rocuronium was ascertained via the titration method in this study. Titrated group required significantly less sugammadex to achieve a TOFR of at least 0.9 compared to recommended group (P < 0.001). Residual paralysis incidence was similar between groups (5.4% in titrated group vs. 4.9% in recommended group; P = 0.564). Although recovery time was longer in titrated group, extubation time and length of stay in the PACU were comparable.
conclusionsTitrated sugammadex administration significantly reduces required dosage without increasing residual paralysis risk. Continuous neuromuscular monitoring postoperatively is strongly recommended due to individual variability in dosage needs.
trial registrationThe study was registered in the Chinese Clinical Trial Registry on March 4, 2024(ChiCTR2400081540).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.